Literature DB >> 1317914

Cisplatin neuropathy: clinical course and neurophysiological findings.

M LoMonaco1, M Milone, A P Batocchi, L Padua, D Restuccia, P Tonali.   

Abstract

Sixteen patients treated with cisplatin (CDDP) 40 mg/m2 on days 1-5 every 4 weeks for three courses (cumulative dose 600 mg/m2) were clinically and neurophysiologically tested before, during and 1, 3, 6, 9 and 12 months after CDDP administration. The first symptoms of polyneuropathy occurred in 4 of 9 patients after the second course (cumulative dose 400 mg/m2). One month after treatment 1 of 9 patients was asymptomatic, 5 complained of symptoms and 3 showed clinical and neurophysiological signs of polyneuropathy. Three months after CDDP all patients were affected. Clinical and neurophysiological signs of severity progression were noted up to 6 months after treatment with CDDP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317914     DOI: 10.1007/bf00839140

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Prospective nerve conduction studies in cisplatin therapy.

Authors:  J E Riggs; M Ashraf; R D Snyder; L Gutmann
Journal:  Ann Neurol       Date:  1988-01       Impact factor: 10.422

2.  Polyneuropathy induced by cisplatin.

Authors:  B W Ongerboer de Visser; G Tiessens
Journal:  Prog Exp Tumor Res       Date:  1985

3.  Severe sensorimotor neuropathy after cisplatin therapy.

Authors:  M Pagès; A M Pagès; L Bories-Azeau
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-03       Impact factor: 10.154

4.  Drug-induced peripheral neuropathies.

Authors:  Z Argov; F L Mastaglia
Journal:  Br Med J       Date:  1979-03-10

5.  Cisplatin neuropathy with Lhermitte's sign.

Authors:  J Dewar; H Lunt; D A Abernethy; P Dady; L F Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

6.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

Authors:  S W Thompson; L E Davis; M Kornfeld; R D Hilgers; J C Standefer
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

7.  Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin.

Authors:  G K Daugaard; J Petrera; W Trojaborg
Journal:  Acta Neurol Scand       Date:  1987-08       Impact factor: 3.209

8.  Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up.

Authors:  B J Roth; A Greist; P S Kubilis; S D Williams; L H Einhorn
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

9.  cis-Platinum-induced hypomagnesemia and peripheral neuropathy.

Authors:  M Ashraf; P L Scotchel; J M Krall; E B Flink
Journal:  Gynecol Oncol       Date:  1983-12       Impact factor: 5.482

10.  Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy.

Authors:  S Ostrow; D Hahn; P H Wiernik; R D Richards
Journal:  Cancer Treat Rep       Date:  1978-10
View more
  20 in total

1.  Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry.

Authors:  Floortje Mols; Antoinetta J M Beijers; Gerard Vreugdenhil; Anna Verhulst; Goof Schep; Olga Husson
Journal:  J Cancer Surviv       Date:  2015-04-16       Impact factor: 4.442

2.  Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes.

Authors:  Tejaswi Kandula; Michelle Anne Farrar; Richard J Cohn; David Mizrahi; Kate Carey; Karen Johnston; Matthew C Kiernan; Arun V Krishnan; Susanna B Park
Journal:  JAMA Neurol       Date:  2018-08-01       Impact factor: 18.302

Review 3.  Neurologic Complications of Commonly Used Drugs in the Hospital Setting.

Authors:  Elliot T Dawson; Sara E Hocker
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

4.  Persistent mobility disability after neurotoxic chemotherapy.

Authors:  Elizabeth S Hile; G Kelley Fitzgerald; Stephanie A Studenski
Journal:  Phys Ther       Date:  2010-09-02

5.  Premature aging-related peripheral neuropathy in a mouse model of progeria.

Authors:  James R Goss; Donna Beer Stolz; Andria Rasile Robinson; Mingdi Zhang; Norma Arbujas; Paul D Robbins; Joseph C Glorioso; Laura J Niedernhofer
Journal:  Mech Ageing Dev       Date:  2011-05-11       Impact factor: 5.432

6.  A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.

Authors:  Debra L Barton; Edward J Wos; Rui Qin; Bassam I Mattar; Nathan Benjamin Green; Keith S Lanier; James Dewitt Bearden; John W Kugler; Kay L Hoff; Pavan S Reddy; Kendrith M Rowland; Mike Riepl; Bradley Christensen; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-05-25       Impact factor: 3.603

7.  The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.

Authors:  Sherry L Wolf; Debra L Barton; Rui Qin; Edward J Wos; Jeff A Sloan; Heshan Liu; Neil K Aaronson; Daniel V Satele; Bassam I Mattar; Nathan B Green; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2011-04-12       Impact factor: 3.603

8.  Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Authors:  Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

Review 9.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy.

Authors:  Anna Dzagnidze; Zaza Katsarava; Julia Makhalova; Bernd Liedert; Min-Suk Yoon; Holger Kaube; Volker Limmroth; Juergen Thomale
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.